Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

- August 21st, 2018

Astellas Pharma (TSE:4503) and Ironwood Pharmaceuticals (Nasdaq:IRWD) announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg for the additional indication of chronic constipation. As quoted in the press release: Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas. It … Continued

Astellas Pharma (TSE:4503) and Ironwood Pharmaceuticals (Nasdaq:IRWD) announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg for the additional indication of chronic constipation.

As quoted in the press release:

Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas. It was approved in Japan in December 2016 for the indication of irritable bowel syndrome with constipation (IBS-C)2, and has been on the Japanese market since March 2017.

This approval is based on the results of a Phase 3, double-blind, placebo-controlled, parallel group trial conducted to evaluate the efficacy and safety of linaclotide orally administered for 4 weeks in 186 Japanese patients with chronic constipation. The subjects were randomly assigned to either the linaclotide (0.5 mg) or placebo group in a 1:1 ratio. In the linaclotide group, the change in weekly mean frequency of spontaneous bowel movement (SBM)3 at 1 week after the start of administration, which was the primary endpoint, represented a statistically significant improvement as compared to the placebo group. The most common adverse event was diarrhea, and its severity was mild to moderate in all cases.

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Leave a Reply